You might have something there..., but at what price. A few years back before the reverse split I think they were offered $5 per share and the then management team turned it down. Share holder have to be careful before accepting any offer without understanding value of assets that includes the ones they have invested in in the current clinical trials and that is not easy to calculate either. Just based on the reverse split and the offer to buy before that we'd be around $20-25. It is highly unlikely that price would not be offered unless a biding war came into play.
Just to add some color...unlike then, there is now one bio-savvy party who owns 30% of the shares O/S, and another 20% by other like-minded funds. Following the money, that means there is definitely some meat on the bone now. Sept and Oct are going to be very interesting, I'm surprised almost all the q's last night were on Eyeguard delays and not fishing for OA and acne info.